EX-99.40 41 d929223dex9940.htm EX-99.40 EX-99.40

 

Exhibit 99.40

 

Akumin Inc.

 

Condensed Interim Consolidated Financial Statements (Unaudited)

September 30, 2019

(expressed in US dollars unless otherwise stated)

 
 

Akumin Inc.

Table of Contents

 

   
  Page
   
Condensed Interim Consolidated Financial Statements (Unaudited)  
   
Condensed Interim Consolidated Balance Sheets 1
   
Condensed Interim Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) 2
   
Condensed Interim Consolidated Statements of Changes in Equity 3
   
Condensed Interim Consolidated Statements of Cash Flows 4
   
Notes to Condensed Interim Consolidated Financial Statements 5 – 33
 
 

Akumin Inc.

Condensed Interim Consolidated Balance Sheets

(Unaudited)

 

 

(expressed in US dollars unless otherwise stated)

 

    September 30,
2019
    December 31,
2018
 
    $     $  
Assets                
                 
Current assets                
Cash     17,475,988       19,326,412  
Accounts receivable (note 5)     77,163,237       29,810,501  
Prepaid expenses and other current assets     1,278,990       1,049,285  
                 
      95,918,215       50,186,198  
                 
Security deposits and other assets     1,920,142       815,450  
Property and equipment (note 6)     195,952,278       55,567,588  
Goodwill     330,828,387       130,539,869  
Intangible assets     11,941,832       3,668,596  
                 
      636,560,854       240,777,701  
Liabilities                
                 
Current liabilities                
Accounts payable and accrued liabilities     24,333,175       16,865,477  
Leases (note 8)     10,108,461       851,183  
Senior loans payable (note 9)     3,701,167       2,867,167  
                 
      38,142,803       20,583,827  
                 
Leases (note 8)     122,176,433       3,325,832  
                 
Senior loans payable (note 9)     316,848,786       108,801,431  
                 
Derivative financial instruments     1,224,331        
                 
Subordinated notes payable (note 10)           1,492,233  
Subordinated notes payable – earn-out (note 10)     180,657       169,642  
Earn-out liability (note 7)     20,534,510        
                 
      499,107,520       134,372,965  
Shareholders’ Equity                
                 
Common shares (note 11)     149,777,252       123,746,423  
Warrants (note 11)     783,264       1,742,910  
Contributed surplus     7,571,380       5,088,376  
                 
Deficit     (23,444,336 )     (26,640,173 )
                 
Equity attributable to shareholders of Akumin Inc.     134,687,560       103,937,536  
Non-controlling interests     2,765,774       2,467,200  
                 
      137,453,334       106,404,736  
                 
      636,560,854       240,777,701  

Commitments and contingencies (note 12)

Subsequent events (note 17)                

Approved by the Board of Directors

(signed) “Riadh Zine”     Director     (signed) “Tom Davies” Director  
                     

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

( 1 )
 

Akumin Inc.

Condensed Interim Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)

(Unaudited)

 

 

(expressed in US dollars unless otherwise stated) 

                         
    Three-month     Three-month     Nine-month     Nine-month  
    period ended     period ended     period ended     period ended  
    September 30,     September 30,     September 30,     September 30,  
    2019     2018     2019     2018  
    $     $     $     $  
Revenue                                
Service fees – net of allowances and discounts     68,223,340       38,316,457       168,588,127       107,243,804  
Other revenue     650,592       814,139       1,822,142       2,086,732  
                                 
      68,873,932       39,130,596       170,410,269       109,330,536  
                                 
Expenses                                
Employee compensation     23,793,719       14,733,517       60,457,981       38,387,117  
Reading fees     9,475,721       5,142,654       24,242,249       14,795,857  
Rent and utilities     2,736,123       4,292,354       6,934,956       11,461,327  
Third-party services and professional fees     5,121,945       3,003,890       12,637,341       8,706,414  
Administrative     3,253,288       1,778,987       8,897,585       6,360,998  
Medical supplies and other     1,796,556       1,383,446       4,938,733       4,104,805  
Depreciation and amortization     8,142,100       2,576,851       20,907,240       6,848,850  
Stock-based compensation     852,588       1,423,998       2,805,541       4,464,565  
Interest expense     9,591,686       1,482,079       18,361,443       4,200,877  
Impairment of property and equipment                       638,336  
Settlement costs (recoveries)     (207,961 )     (99,100 )     (1,438,662 )     29,494  
Acquisition-related costs     443,944       255,954       2,993,629       919,602  
Public offering costs                       813,545  
Financial instruments revaluation and other (gains) losses     1,693,061       2,425,933       3,744,575       2,318,994  
                                 
      66,692,770       38,400,563       165,482,611       104,050,781  
                                 
Income before income taxes     2,181,162       730,033       4,927,658       5,279,755  
Income tax provision (recovery)     (397,519 )     23,648       147,928       327,038  
                                 
Net income and comprehensive income for the period     2,578,681       706,385       4,779,730       4,952,717  
Non-controlling interests     590,517       511,389       1,583,893       2,162,027  
                                 
Net income attributable to common shareholders     1,988,164       194,996       3,195,837       2,790,690  
                                 
Net income per share (note 15)                                
Basic and diluted     0.03       0.00       0.05       0.05  

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

( 2 )
 

Akumin Inc.

Condensed Interim Consolidated Statements of Changes in Equity

(Unaudited)

 

 

(expressed in US dollars unless otherwise stated)

 

    Common
shares
$
    Warrants
$
    Contributed
surplus
$
    Deficit
$
    Non-
controlling
interest
$
    Total
equity
$
 
Balance – December 31, 2017     83,771,904       1,310,661       2,205,784       (13,223,745 )     6,340,583       80,405,187  
Acquisition of non-controlling interests                       (18,416,229 )     (3,074,268 )     (21,490,497 )
Net income and comprehensive income                       2,790,690       2,162,027       4,952,717  
Issuance of common shares – net of issuance costs                                                
Acquisition consideration     3,709,588                               3,709,588  
Public offering     32,444,362                               32,444,362  
Warrants exercised     1,000,766       (302,130 )                       698,636  
Issuance of warrants           734,379                         734,379  
Stock-based compensation                 4,464,565                   4,464,565  
Payment to non-controlling interests                             (2,879,593 )     (2,879,593 )
                                                 
Balance – September 30, 2018     120,926,620       1,742,910       6,670,349       (28,849,284 )     2,548,749       103,039,344  
                                                 
Balance – December 31, 2018     123,746,423       1,742,910       5,088,376       (26,640,173 )     2,467,200       106,404,736  
Net income and comprehensive income                       3,195,837       1,583,893       4,779,730  
Issuance of common shares – net of issuance costs                                                
Acquisition consideration     23,437,500                               23,437,500  
RSUs and warrants exercised     2,593,329       (569,733 )     (712,450 )                 1,311,146  
Warrants expired           (389,913 )     389,913                    
Stock-based compensation expense                 2,805,541                   2,805,541  
Payment to non-controlling interests                             (1,285,319 )     (1,285,319 )
                                                 
Balance – September 30, 2019     149,777,252       783,264       7,571,380       (23,444,336 )     2,765,774       137,453,334  

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

( 3 )
 

Akumin Inc.
Condensed Interim Consolidated Statements of Cash Flows

(Unaudited)

 

 

(expressed in US dollars unless otherwise stated)

 

    Nine-month
period ended
September 30,
2019
$
    Nine-month
period ended
September 30,
2018
$
 
Cash flows provided by (used in)                
Operating activities                
Net income for the period     4,779,730       4,952,717  
Adjustments for                
Depreciation and amortization     20,907,240       6,848,850  
Stock-based compensation     2,805,541       4,464,565  
Impairment of property and equipment           638,336  
Interest expense accretion of debt     1,184,446       475,500  
Deferred income tax recovery     (422,056 )      
Financial instruments revaluation and other (gains) losses     3,744,575       2,318,994  
Changes in non-cash working capital                
Accounts receivable     (21,624,658 )     (11,807,476 )
Prepaid expenses, security deposits and other assets     (1,061,267 )     (500,821 )
Accounts payable and accrued liabilities     459,501       (4,545,786 )
                 
      10,773,052       2,844,879  
                 
Investing activities                
Property and equipment and intangible assets     (9,338,197 )     (5,891,514 )
Business acquisitions – net of cash acquired     (201,095,758 )     (23,315,703 )
                 
      (210,433,955 )     (29,207,217 )
                 
Financing activities                
Loan proceeds     333,600,000       100,000,000  
Loan repayments     (112,963,650 )     (76,029,409 )
Issuance costs – loans     (14,781,765 )     (2,211,914 )
Leases – principal payments     (6,569,933 )     (388,467 )
Subordinated notes     (1,500,000 )      
Common shares     1,311,146       35,698,637  
Equity issuance costs           (1,821,260 )
Acquisition of non-controlling interests           (17,780,909 )
Payment to non-controlling interests     (1,285,319 )     (2,879,593 )
                 
      197,810,479       34,587,085  
                 
Increase (decrease) in cash during the period     (1,850,424 )     8,224,747  
Cash – Beginning of period     19,326,412       12,145,481  
                 
Cash – End of period     17,475,988       20,370,228  
                 
Supplementary information                
Interest expense paid     17,280,037       3,727,548  
Income taxes paid     560,388       424,653  

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

( 4 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

1 Presentation of condensed interim consolidated financial statements and nature of operations

The operations of Akumin Inc. (Akumin or the Company) and its Subsidiaries (defined below) primarily consist of operating outpatient diagnostic imaging centres located in Florida, Delaware, Georgia, Pennsylvania, Texas, Illinois and Kansas. Substantially all of the centres operated by Akumin were obtained through acquisition. Related to its imaging centre operations, Akumin also operates a medical equipment business, SyncMed, LLC (SyncMed), which provides maintenance services to Akumin’s imaging centres in Texas, Illinois and Kansas and a billing and revenue cycle management business, Rev Flo Inc., whose operations were merged into Akumin’s wholly owned subsidiary, Akumin Corp., on December 31, 2018.

The services offered by the Company (through the Subsidiaries) include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography (X-ray), fluoroscopy and other related procedures.

The Company has a diverse mix of payers, including private, managed care capitated and government payers.

The registered and head office of Akumin is located at 151 Bloor Street West, Suite 603, Toronto, Ontario, M5S 1S4. All operating activities are conducted through its wholly owned US subsidiary, Akumin Holdings Corp. and the wholly owned subsidiaries of Akumin Holdings Corp., namely, Akumin Corp., Akumin Florida Holdings, LLC, formerly known as Tri-State Imaging FL Holdings, LLC (FL Holdings), Akumin Imaging Texas, LLC, formerly known as Preferred Medical Imaging, LLC (PMI), SyncMed, Akumin FL, LLC (Akumin FL) and Advanced Diagnostics Group, LLC (ADG) (collectively, the Subsidiaries), all of which are located in the United States.

2 Basis of preparation

These condensed interim consolidated financial statements for the three and nine months ended September 30, 2019 have been prepared in accordance with International Accounting Standard (IAS) 34, Interim Financial Reporting. The disclosures contained in these condensed interim consolidated financial statements do not include all of the requirements of International Financial Reporting Standards (IFRS) for annual financial statements. The condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2018 and for the fifteen months ended December 31, 2017, which have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board (IASB). The condensed interim consolidated financial statements are based on accounting policies as described in the December 31, 2018 consolidated financial statements, except for changes to the accounting policies described in note 3.

Certain comparative information has been reclassified to conform with the presentation adopted in the current fiscal period.

The condensed interim consolidated financial statements include all of the accounts of the Company and the Subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

( 5 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

On November 13, 2019, the Board of Directors (the Board) authorized the condensed interim consolidated financial statements for issuance.

 

3 Summary of significant accounting policies

These condensed interim consolidated financial statements have been prepared using the significant accounting policies consistent with those applied in the Company’s December 31, 2018 consolidated financial statements, except as described below relating to the adoption of IFRS 16, Leases (IFRS 16) and International Financial Reporting Interpretations Committee (IFRIC) 23.

The Company adopted IFRS 16 as at January 1, 2019, with modified retrospective application without restatement of prior year comparatives. Another new standard was also adopted as at January 1, 2019, IFRIC 23, Uncertainty over Income Tax Treatments, but it does not have a material effect on the Company’s condensed interim consolidated financial statements.

Adoption of IFRS 16

During 2016, the IASB issued IFRS 16, Leases (IFRS 16), replacing IAS 17, Leases (IAS 17) and related interpretations. The standard introduces a single, on-balance sheet recognition and measurement model for lessees, eliminating the distinction between operating and finance leases. Lessees recognize a right-of-use asset representing its control of and right to use the underlying asset and a lease liability representing its obligation to make future lease payments. As a result of adoption of IFRS 16 on January 1, 2019, the Company has recognized an increase of $110,902,436 to both property and equipment and lease liabilities on its condensed interim consolidated balance sheets. Lessor accounting remains similar to IAS 17.

IFRS 16 became effective for annual periods beginning on or after January 1, 2019. For leases where the Company is the lessee, it had the option of adopting a fully retrospective approach or a modified retrospective approach on transition to IFRS 16. The Company adopted the standard on January 1, 2019 using the modified retrospective approach. The Company applied the requirements of the standard retrospectively with no restatement of the comparative period. Under the modified retrospective approach, the Company chose to measure all right-of-use assets retrospectively as if the standard had been applied since lease commencement dates, which is January 1, 2019 for purposes of the Company’s IFRS 16 adoption. Substantially all of the Company’s operating leases are real estate leases for its imaging centres and corporate offices and for medical equipment. Other leased assets include office equipment. The Company recognized right-of-use assets and lease liabilities for its operating leases except for certain classes of underlying assets in which the underlying asset was considered to be of low-value; however, the Company may choose to elect the recognition exemptions regarding short-term leases on a class-by-class basis for new classes, and lease-by-lease basis, respectively, in the future. Due to the removal of rent expense for leases, the Company’s operating expenses are reduced with a corresponding increase to depreciation and an increase to interest costs (due to accretion of the lease liability). There are no significant impacts to the Company’s existing finance leases under IAS 17 as a lessee.

( 6 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

IFRS 16 permits the use of recognition exemptions and practical expedients. The Company applied the following recognition exemptions and practical expedients:

· grandfathered the definition of leases for existing contracts at the date of initial application;
· excluded certain low-value leases from IFRS 16 lease accounting;
· applied a single discount rate to a portfolio of leases with reasonably similar characteristics at the date of initial application;
· excluded initial direct costs from the measurement of right-of-use assets at the date of initial application;
· used hindsight in determining lease term at the date of initial application; and
· relied on its assessment of whether leases are onerous applying IAS 37, Provisions, Contingent Liabilities and Contingent Assets, immediately before the date of initial application as an alternative to performing an impairment review.

The Company used its incremental borrowing rates as at January 1, 2019 to measure lease liabilities. The weighted average incremental borrowing rate for total lease liabilities as at January 1, 2019 was 6.0%. Prior to adopting IFRS 16, the Company’s total minimum operating lease commitments as at December 31, 2018 were $163,728,644 (note 15 of the Company’s 2018 annual financial statements). These lease commitments included expected exercise of optional renewal terms for most of the leases. The difference between this amount and the lease liabilities of $110,902,436 recognized on transition on January 1, 2019 was due to the effect of discounting on the minimum lease payments.

Changes to accounting policies for leases

The Company did not restate prior year comparative information under the modified retrospective approach. Therefore, the comparative information continues to be reported under IAS 17 and related interpretations.

Lessee accounting policy as a lessee

Applicable from January 1, 2019, the Company recognizes a right-of-use asset and a lease liability based on the present value of future lease payments when a lessor makes the leased asset available for use by the Company. Lease payments for assets that are exempt through the low-value exemption are recognized in operating expenses. The measurement of lease liabilities includes the fixed and in-substance fixed payments and variable lease payments that depend on an index or a rate, less any lease incentives receivable. Certain leases require the Company to make payments that relate to property taxes, insurance and other non-rental costs. These costs are typically variable and are not included in the calculation of the right-of-use asset or lease liability. If applicable, lease liabilities will also include the purchase option exercise price if the Company is reasonably certain to exercise that option, termination penalties if the lease term also reflects the termination option and amounts expected to be payable under a residual value guarantee. Subsequent to initial measurement, the Company measures lease liabilities at amortized cost using the effective interest method. Lease liabilities are remeasured when there is a change in lease term, a change in the assessment of an option to purchase the leased asset, a change in expected residual value guarantee, or a change in future lease payments.

( 7 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

The right-of-use assets are measured at the initial amount of the lease liabilities plus any lease payments made at or before the commencement date net of lease incentives received, and decommissioning costs. Subsequent to initial measurement, the Company applies the cost model to the right-of-use assets with the exception of the fair value model application to right-of-use assets that meet the definition of investment property in IAS 40, Investment Property. Right-of-use assets are measured at cost less accumulated depreciation, accumulated impairment losses governed by IAS 36 and any remeasurements of lease liabilities. The assets are depreciated on a straight-line basis over the earlier of the end of the assets’ useful lives or the end of the lease terms.

Discount rates used in the present value calculation are the interest rates implicit in the leases, or if the rates cannot be readily determined, the Company’s incremental borrowing rates. Lease terms applied are the contractual non-cancellable periods of the leases plus periods covered by an option to renew the leases if the Company expects to exercise that option and the periods covered by an option to terminate the leases if the Company expects not to exercise that option.

The Company has elected to not separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.

Critical accounting estimates and judgments for leases

The management exercises judgment in determining the appropriate lease term on a lease-by-lease basis. The management considers all facts and circumstances that create an economic incentive to exercise a renewal option or to not exercise a termination option including operational performance and past business practice. The periods covered by renewal options are only included in the lease term if the management expects to renew. Changes in the economic environment or changes in the industry may impact the management’s assessment of lease term, and any changes in the management’s estimate of lease terms may have a material impact on the Company’s condensed interim consolidated balance sheets and the condensed interim consolidated statements of net income (loss) and comprehensive income (loss).

In determining the carrying amount of right-of-use assets and lease liabilities, the Company is required to estimate the incremental borrowing rate specific to each leased asset or portfolio of leased assets if the interest rate implicit in the lease is not readily determined. The management determines the incremental borrowing rate of each leased asset by incorporating the Company’s creditworthiness, the security, term and value of the underlying leased asset, and the economic environment in which the leased asset operates. The incremental borrowing rates are subject to change mainly due to macroeconomic changes in the environment.

( 8 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

4 Business combinations
i) On April 1, 2019, the Company acquired, through a subsidiary, a single outpatient diagnostic imaging centre in Davie, Florida, for cash consideration of approximately $450,000 (Davie Acquisition). In accordance with the transaction agreement, $50,000 of this purchase price (Holdback Fund) was withheld as security for indemnity obligations and was released to the seller on October 1, 2019. The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows:

 

    $  
Assets acquired      
Non-current assets        
Property and equipment     170,000  
Real estate (right-of-use)     427,558  
         
      597,558  
         
Liabilities assumed        
Non-current liabilities        
Leases     427,558  
         
Net assets acquired     170,000  
Goodwill     280,000  
         
Purchase price     450,000  

This acquisition was an opportunity for the Company to increase its economies of scale across Florida. The goodwill assessed on acquisition, expected to be deductible for income tax purposes, reflects the Company’s expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of this acquisition have been included in the Company’s consolidated statements of net income (loss) and comprehensive income (loss) from the acquisition date. Since the acquisition date, this acquisition contributed revenue of approximately $252 thousand and loss before tax of approximately $7 thousand to the Company’s consolidated results for the nine months ended September 30, 2019.

The Company has estimated the contribution to the Company’s consolidated results from this acquisition had the business combination occurred at the beginning of the year. Had the business combination occurred at the beginning of fiscal 2019, this business combination would have contributed approximately $376 thousand in revenue and $10 thousand in loss before tax for the nine months ended September 30, 2019, and consolidated pro forma revenue and income before tax for the same period would have been approximately $170.5 million and $3.3 million, respectively. These estimates should not be used as an indicator of past or future performance of the Company or the acquisition.

( 9 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

ii) On April 15, 2019, the Company announced that it had, through a subsidiary, entered into purchase agreements to acquire 27 imaging centres (Florida – 21 and Georgia – 6) operated under ADG, The Imaging Centers of West Palm and Elite Radiology of Georgia. All of these centres were managed by ADG’s management team. On May 31, 2019, the Company announced the closing of these acquisitions. Pursuant to the purchase agreements, the Company acquired all of the issued and outstanding equity interests of ADG Acquisition Holdings, Inc., TIC Acquisition Holdings, LLC and SFL Radiology Holdings, LLC (the ADG Acquisitions).

 

The total purchase price for the ADG Acquisitions at closing (including preliminary working capital adjustments and payment for cash acquired) was approximately $216.0 million, of which $23.4 million was satisfied by the issuance of 6.25 million common shares of the Company at a price of $3.75 per share based on the share price at the close of May 31, 2019. The balance of this purchase price was mostly financed through the Term Loans (note 9). A portion of the purchase price payable in respect of the acquisition of SFL Radiology Holdings, LLC is subject to an earn-out based on annualized revenues earned in the first two quarters of 2020 less certain costs (note 7).

The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows. Intangible assets include covenant not to compete, trade name and license arrangements. A deferred tax liability was assumed as part of the net assets acquired in the ADG Acquisitions. The Company has utilized unrecognized tax benefits against this deferred tax liability, which resulted in an income tax recovery of the same amount during the three-month period ended September 30, 2019.

 

    September 30,     June 30,  
    2019     2019  
    $     $  
             
Assets acquired                
Current assets                
Cash     3,524,331       3,524,331  
Accounts receivable     19,418,814       19,418,814  
Prepaid expenses     269,012       269,012  
                 
      23,212,157       23,212,157  
                 
Non-current assets                
Property and equipment     11,508,940       11,508,940  
Intangible assets     9,010,000        
Real estate and equipment (right-of-use)     16,626,110       16,626,110  
                 
      37,145,050       28,135,050  
                 
      60,357,207       51,347,207  
( 10 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

             
    September 30,     June 30,  
    2019     2019  
    $     $  
Liabilities assumed                
Current liabilities                
Accounts payable and accrued liabilities     5,927,161       5,927,161  
                 
Non-current liabilities                
ADG Acquisition – earn-out (note 7)     19,968,307       19,968,307  
Deferred tax liability     422,056        
Leases     16,626,110       16,626,110  
                 
      37,016,473       36,594,417  
                 
      42,943,634       42,521,578  
                 
Net assets acquired     17,413,573       8,825,629  
Goodwill     198,615,203       207,203,147  
                 
Purchase price     216,028,776       216,028,776  

These acquisitions were an opportunity for the Company to increase its economies of scale across Florida and enter the Georgia market. The goodwill assessed on acquisition, expected to not be deductible for income tax purposes, reflects the Company’s expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of these acquisitions have been included in the Company’s condensed interim consolidated statements of net income (loss) and comprehensive income (loss) from the acquisition date. Since the acquisition date, these acquisitions contributed revenue of approximately $24.4 million and income before tax of approximately $9.9 million to the Company’s consolidated results for the nine months ended September 30, 2019.

The Company has estimated the contribution to the Company’s consolidated results from these acquisitions had the business combination occurred at the beginning of the year. Had the business combination occurred at the beginning of fiscal 2019, this business combination would have contributed approximately $54.9 million in revenue and $22.1 million in income before tax for the nine months ended September 30, 2019, and consolidated pro forma revenue and income before tax for the same period would have been approximately $200.9 million and $15.6 million, respectively. These estimates should not be used as an indicator of past or future performance of the Company or the acquisition.

( 11 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

iii) On May 31, 2019, the Company acquired, through a subsidiary, a single outpatient diagnostic imaging centre in Deltona, Florida, for a cash consideration of $648,387 (Deltona Acquisition). The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows:
    $  
       
Assets acquired        
Non-current assets        
Property and equipment     295,000  
Real estate (right-of-use)     154,136  
         
      449,136  
         
Liabilities assumed        
Current liabilities        
Accounts payable and accrued liabilities     57,880  
Non-current liabilities        
Leases     154,136  
         
      212,016  
         
Net assets acquired     237,120  
Goodwill     411,267  
         
Purchase price     648,387  

This acquisition was an opportunity for the Company to increase its economies of scale across Florida. The goodwill assessed on acquisition, expected to be deductible for income tax purposes, reflects the Company’s expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of this acquisition have been included in the Company’s consolidated statements of net income (loss) and comprehensive income (loss) from the acquisition date. Since the acquisition date, this acquisition contributed revenue of approximately $1.1 million and income before tax of approximately $0.3 million to the Company’s consolidated results for the nine months ended September 30, 2019.

The Company has estimated the contribution to the Company’s consolidated results from this acquisition had the business combination occurred at the beginning of the year. Had the business combination occurred at the beginning of fiscal 2019, this business combination would have contributed approximately $2.4 million in revenue and $0.7 million in income before tax for the nine months ended September 30, 2019, and consolidated pro forma revenue and income before tax for the same period would have been approximately $171.7 million and $3.7 million, respectively. These estimates should not be used as an indicator of past or future performance of the Company or the acquisition.

( 12 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

iv) On August 16, 2019, the Company acquired, through a subsidiary, five outpatient diagnostic imaging centres in El Paso, Texas, for cash consideration of approximately $11 million (El Paso Acquisition). The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows. The intangible assets consist of the trade name and covenants not to compete.

 

    $  
Assets acquired        
Current assets        
Accounts receivable     1,275,726  
Prepaid expenses     19,789  
         
      1,295,515  
Non-current assets        
Property and equipment     3,922,481  
Real estate (right-of-use)     3,612,019  
Intangible assets     720,000  
         
      9,550,015  
Liabilities assumed        
Current liabilities        
Accounts payable and accrued liabilities     1,024,631  
         
Non-current liabilities        
Leases     3,612,019  
         
      4,636,650  
         
Net assets acquired     4,913,365  
Goodwill     6,086,635  
         
Purchase price     11,000,000  

This acquisition was an opportunity for the Company to increase its economies of scale across Texas. The goodwill assessed on acquisition, expected to be deductible for income tax purposes, reflects the Company’s expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of this acquisition have been included in the Company’s consolidated statements of net income (loss) and comprehensive income (loss) from the acquisition date. Since the acquisition date, this acquisition contributed revenue of approximately $1.7 million and income before tax of approximately $0.6 million to the Company’s consolidated results for the nine months ended September 30, 2019.

The Company has estimated the contribution to the Company’s consolidated results from this acquisition had the business combination occurred at the beginning of the year. Had the business combination occurred at the beginning of fiscal 2019, this business combination would have contributed approximately $10.4 million in revenue and $3.3 million in income before tax for the nine months ended September 30, 2019, and consolidated pro forma revenue and income before tax for the same period would have been approximately $179.1 million and $6.1 million, respectively. These estimates should not be used as an indicator of past or future performance of the Company or the acquisition.

( 13 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

v) On November 1, 2018, the Company acquired, through a subsidiary, a single outpatient diagnostic imaging centre in Kissimmee, Florida, for a cash consideration of approximately $1.2 million (Kissimmee Acquisition), which was partly financed through the Syndicated Revolving Facility (note 9). The Company has made a fair value determination of the acquired assets and assumed liabilities as follows. During the three months ended September 30, 2019, the Company updated the fair value of the net accounts receivable based on greater visibility about the business operations.

 

    September 30,     March 31,     December 31,  
    2019     2019     2018  
    $     $     $  
Assets acquired                  
Current assets                        
Accounts receivable     265,741       521,034        
                         
Non-current assets                        
Security deposits     48,000       48,000       48,000  
Property and equipment     282,500       282,500       282,500  
                         
      330,500       330,500       330,500  
                         
      596,241       851,534       330,500  
Liabilities assumed                        
Current liabilities                        
Accounts payable and accrued liabilities     116,440       116,440       117,916  
                         
Net assets acquired     479,801       735,094       212,584  
Goodwill     810,607       555,314       1,012,416  
                         
Purchase price     1,290,408       1,290,408       1,225,000  

 

vi) On November 9, 2018, the Company acquired four outpatient diagnostic imaging centres in Broward County, Florida, for a cash consideration of approximately $12.1 million (Broward Acquisition), which included assumption of leases (excluding right to use assets) of approximately $1.3 million. It was partly financed through the Syndicated Revolving Facility (note 9). The Company has made a fair value determination of the acquired assets and assumed liabilities as follows. The intangible assets consist of the trade name and covenants not to compete. During the three months ended September 30, 2019, the Company updated the fair value of the net accounts receivable based on greater visibility about the business operations.
( 14 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

    September 30,     March 31,     December 31,  
    2019     2019     2018  
    $     $     $  
                         
Assets acquired                        
Current assets                        
Accounts receivable     1,568,533       2,635,890        
Prepaid expenses     53,100       53,100       53,100  
                         
      1,621,633       2,688,990       53,100  
Non-current assets                        
Property and equipment     2,662,363       2,662,363       2,662,363  
Intangible assets     740,000       740,000       740,000  
                         
      3,402,363       3,402,363       3,402,363  
                         
      5,023,996       6,091,353       3,455,463  
                         
Liabilities assumed                        
Current liabilities                        
Accounts payable and accrued liabilities     863,871       863,871       863,871  
Non-current liabilities                        
Finance leases     1,256,413       1,256,413       1,256,413  
                         
      2,120,284       2,120,284       2,120,284  
                         
Net assets acquired     2,903,712       3,971,069       1,335,179  
Goodwill     7,756,873       6,689,516       9,460,388  
                         
Purchase price     10,660,585       10,660,585       10,795,567  

 

5 Accounts receivable

    September 30,
2019
$
    December 31,
2018
$
 
                 
Accounts receivable     94,224,004       38,284,265  
Less: Allowance for credit losses     17,060,767       8,473,764  
                 
      77,163,237       29,810,501  

 

The allowance for credit losses includes a provision for credit losses expense for the three and nine months ended September 30, 2019 of $4,405,139 and $8,587,003, respectively (2018 – $1,648,313 and $4,815,334).

( 15 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

6 Property and equipment and real estate and equipment (right-of-use assets)

 

Property and equipment              

 

    Furniture                       Equipment              
    and     Office     Leasehold     Medical     under finance     Computer        
    fixtures     equipment     improvements     equipment     leases     equipment     Total  
    $     $     $     $     $     $     $  
Cost                                                        
Balance – December 31, 2017     533,434       186,097       8,880,333       37,043,853       7,481,192       86,165       54,211,074  
Additions     143,920       2,140       518,516       8,977,339       924,625       23,161       10,589,701  
Business acquisitions                 682,635       11,362,768       1,256,413             13,301,816  
Disposals                       (861,067 )                 (861,067 )
Impairment                       (963,335 )                 (963,335 )
                                                         
Balance – December 31, 2018     677,354       188,237       10,081,484       55,559,558       9,662,230       109,326       76,278,189  
Additions     368,441       3,123       2,430,898       6,506,001       2,596,167       53,715       11,958,345  
Business acquisitions     7,650       9,752       3,974,790       11,890,700             13,529       15,896,421  
Disposals                       (271,936 )                 (271,936 )
                                                         
Balance – September 30, 2019     1,053,445       201,112       16,487,172       73,684,323       12,258,397       176,570       103,861,019  
                                                         
Accumulated depreciation                                                        
Balance – December 31, 2017     105,028       86,270       968,363       8,588,397       2,413,325       46,764       12,208,147  
Depreciation     71,790       31,017       847,374       7,120,289       1,065,782       15,831       9,152,083  
Disposals                       (328,975 )                 (328,975 )
Impairment                       (320,654 )                 (320,654 )
                                                         
Balance – December 31, 2018     176,818       117,287       1,815,737       15,059,057       3,479,107       62,595       20,710,601  
Depreciation     68,759       24,121       936,487       7,749,787       1,103,957       19,343       9,902,454  
Disposals                       (82,225 )                 (82,225 )
                                                         
Balance – September 30, 2019     245,577       141,408       2,752,224       22,726,619       4,583,064       81,938       30,530,830  
                                                         
Net book value                                                        
December 31, 2017     428,406       99,827       7,911,970       28,455,456       5,067,867       39,401       42,002,927  
December 31, 2018     500,536       70,950       8,265,747       40,500,501       6,183,123       46,731       55,567,588  
September 30, 2019     807,868       59,704       13,734,948       50,957,704       7,675,333       94,632       73,330,189  

( 16 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

Depreciation expense for the three and nine months ended September 30, 2019 was $3,750,222 and $9,902,454, respectively (2018 – $2,387,576 and $6,395,322). During the three and nine months ended September 30, 2019, the Company had net disposals of $91,549 and $189,711, respectively (2018 – $nil) and impairment of medical equipment and equipment under finance leases of $nil (2018 – $nil and $638,336).

Real estate and equipment (right-of-use assets)

 

    Equipment     Real estate     Total  
    $     $     $  
Cost                        
Balance – December 31, 2018                  
Additions     2,996,488       109,211,697       112,208,185  
Business acquisitions     476,991       20,342,832       20,819,823  
Disposals     (311,665 )     (723,076 )     (1,034,741 )
                         
Balance – September 30, 2019     3,161,814       128,831,453       131,993,267  
                         
Accumulated depreciation                        
Balance – December 31, 2018                  
Depreciation     876,199       8,671,822       9,548,021  
Disposals     (103,888 )     (72,955 )     (176,843 )
                         
Balance – September 30, 2019     772,311       8,598,867       9,371,178  
                         
Net book value                        
December 31, 2018                  
                         
September 30, 2019     2,389,503       120,232,586       122,622,089  

Depreciation expense for the three and nine months ended September 30, 2019 was $3,441,947 and $9,548,022, respectively (2018 – $nil). During the three and nine months ended September 30, 2019, the Company had net disposals of $857,898 (2018 – $nil).

7 Earn-out liability (ADG Acquisition)

 

    September 30,     December 31,  
    2019     2018  
    $     $  
ADG Acquisition – earn-out     20,534,510        

 

A portion of the purchase price payable in respect of the ADG Acquisitions (note 4), specifically for SFL Radiology Holdings, LLC, is subject to an earn-out (the ADG Acquisition – earn-out liability) based on its annualized revenues earned in the first two quarters of 2020 less certain costs including certain operating expenses, capital expenditures and incremental working capital. In accordance with the purchase agreement, 50% of this liability is expected to be settled in the latter half of 2020 and the balance in the first half of 2021.

( 17 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

The value of the ADG Acquisition – earn-out liability has been estimated by management using a probability weighted valuation technique; changes in the fair value of this liability are recognized in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss). Management estimated the fair value of the ADG Acquisition – earn-out liability as at May 31, 2019 of approximately $20.0 million based on a discount rate of 8.75% and management’s estimated probability weighted range of the ADG Acquisition – earn-out liability (it is considered a Level 3 liability as described in note 14). The ADG Acquisition – earn-out liability was revalued at approximately $20.5 million as at September 30, 2019 and the change in fair value was recognized in financial instruments revaluation in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss). As at September 30, 2019, the range of estimated undiscounted ADG Acquisition – earn-out liability is between approximately $17 million and $29 million.

8 Lease liabilities

Finance

As at September 30, 2019, the Company’s finance lease liabilities were $6,059,254 (December 31, 2018 – $4,177,015). Of these obligations, the liabilities due within one year are $1,304,162. Interest expense accrued and paid during the three and nine months ended September 30, 2019 was $73,658 and $189,940, respectively (2018 – $42,633 and $127,538) and lease payments were $214,782 and $639,259, respectively (2018 – $171,438 and $388,467).

Other

As at September 30, 2019, the Company’s other lease liabilities were $126,225,639 (December 31, 2018 – $nil). Of these obligations, the liabilities due within one year are $8,804,299. Interest expense accrued and paid during the three and nine months ended September 30, 2019 was $1,927,858 and $5,205,050, respectively (2018 – $nil) and lease payments were $2,138,120 and $5,930,674, respectively (2018 – $nil).

9 Senior loans payable

The May 2019 Loans, Syndicated Loans and Wesley Chapel Loan are collectively referred to as the Senior Loans.

May 2019 Loans

On May 31, 2019, the Company amended its previous credit agreement dated August 15, 2018 (such amended credit agreement, the May 2019 Credit Agreement) whereby it increased the size of its credit facilities and increased the number of syndicated lenders from five to nine financial institutions. Under the terms of the May 2019 Credit Agreement, the Company received a term loan A and term loan B (Term Loan A, Term Loan B and collectively, Term Loans) of $66,000,000 and $266,000,000, respectively (face value) and a revolving credit facility of $50,000,000, of which $3,300,000 was utilized as at May 31, 2019 (the May 2019 Revolving Facility, and together with the Term Loans, the May 2019 Loans). $16 million of the Term Loan A was subject to a delayed draw, which was drawn (in addition to approximately $1.3 million under the May 2019 Revolving Facility) by the Company in October 2019 to partly finance an acquisition near West Palm Beach, Florida (as

( 18 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

described in note 17). The term of the May 2019 Loans is five years. The May 2019 Loans can be increased by an additional $100,000,000 subject to certain conditions. The proceeds of the Term Loans were used to settle the Syndicated Loans for $112,482,181, the principal outstanding under Subordinated Note and related accrued and unpaid interest for $1,596,250 (note 10), partly finance the ADG Acquisitions and Deltona Acquisition in May 2019 and pay related debt issuance costs. On May 31, 2019, management determined the fair value of the May 2019 Loans to be their face value of $319,300,000 net of debt issuance costs of approximately $14.8 million. The fair value of the May 2019 Loans was determined based on management’s estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 14). In August 2019, the Company used $11 million from the May 2019 Revolving Facility to finance the El Paso Acquisition (note 4) and, as at September 30, 2019, this credit facility had a balance of $17,600,000.

 

    September 30,     December 31,  
    2019     2018  
    $     $  
Term Loan A and May 2019 Revolving Facility     67,475,000        
Term Loan B     251,538,686        
Less: Current portion     (3,320,000 )      
                 
      315,693,686        

 

Subject to the provisions described below, the minimum annual principal payments with respect to the May 2019 Loans (face value) are as follows. This amount includes the increase in debt in October 2019 to partly finance the acquisition near West Palm Beach, Florida (as described in note 17):

 

a) Term Loan A and May 2019 Revolving Facility

 

    $  
October 1, 2019 to December 31, 2019     165,000  
2020     660,000  
2021     1,980,000  
2022     3,795,000  
2023     4,290,000  
2024     73,899,000  
         
      84,789,000  

 

b) Term Loan B

 

    $  
October 1, 2019 to December 31, 2019     665,000  
2020     2,660,000  
2021     2,660,000  
2022     2,660,000  
2023     2,660,000  
2024     254,030,000  
         
      265,335,000  
( 19 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

Effective November 14, 2018, the Company entered into a derivative financial instrument contract with a financial institution in order to mitigate interest rate risk under the variable interest rate Syndicated Loans. The derivative financial instrument is an interest rate cap rate of 3.75% (LIBOR) per annum on a notional amount of 50% of the face value of the Syndicated Term Loan ($50,000,000 as at November 14, 2018). The termination date of this arrangement is August 31, 2021. The cost of this derivative financial instrument was $155,000. The Company has not designated this interest rate cap agreement as a cash flow hedge for accounting purposes. The fair value of this derivative as determined by the financial institution as at September 30, 2019 represented an asset to the Company of $342.

In addition, effective July 31, 2019, the Company entered into a derivative financial instrument, an interest rate collar contract, with a financial institution in order to mitigate interest rate risk under the variable interest rate Term Loans. This derivative financial instrument has an underlying notional amount of 100% of the face value of Term Loan B ($266,000,000 as at July 31, 2019) with (i) a cap rate of 3.00% (LIBOR) per annum and a termination date of July 31, 2022, and (ii) a floor rate of 1.86% (LIBOR) per annum and a termination date of January 31, 2021. There was no upfront cost of this derivative financial instrument. The Company has not designated this interest rate cap agreement as a cash flow hedge for accounting purposes. The fair value of this derivative as determined by the financial institution as at September 30, 2019 represented a liability to the Company of $1,224,331.

Changes in the fair value of these derivatives are recognized in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss).

The May 2019 Credit Agreement provides for the following (capitalized terms used below in this note and not defined elsewhere in these notes have the respective meanings given to them in the May 2019 Credit Agreement):

· Interest

The interest rates payable on the May 2019 Loans are as follows: (i) each Eurodollar Rate Loan shall bear interest on the outstanding principal amount at one-month LIBOR plus Applicable Rate; and (ii) each Base Rate Loan shall bear interest on the outstanding principal amount at the Base Rate (the highest of (a) the Federal Funds Rate plus 0.5%, (b) the prime rate and (c) Eurodollar Rate plus 1.0%) plus Applicable Rate. All advances under the May 2019 Loans are currently classified as Eurodollar Rate Loans. The interest rate paid under the May 2019 Credit Agreement as at September 30, 2019 was approximately 8.1% per annum (September 30, 2018 – nil%). With respect to interest rate sensitivity as at September 30, 2019, a 1% increase in variable interest rates would have increased interest expense for the nine-month period ended September 30, 2019 by approximately $1.1 million (2018 – $nil).

· Payments

 

The minimum principal payment schedule for the May 2019 Loans is noted herein.

( 20 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

· Termination

The termination date of the May 2019 Loans is the earliest of (i) May 31, 2024 and (ii) the date on which the obligations become due and payable pursuant to the May 2019 Credit Agreement.

· Restrictive covenants

In addition to certain covenants, the May 2019 Credit Agreement places limits on the Company’s ability to declare dividends or redeem or repurchase capital stock (including options or warrants), prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions, capital expenditures and asset sales, enter into transactions with affiliates and alter the business the Company and the Subsidiaries currently conduct.

· Financial covenants

 The May 2019 Credit Agreement contains financial covenants including certain leverage ratios and a limit on annual capital expenditures.

The Company is in compliance with the financial covenants and has no events of default under the May 2019 Credit Agreement as at September 30, 2019.

· Events of default

In addition to the above financial covenants, events of default under the May 2019 Credit Agreement include, among others, failure to pay principal of or interest on any May 2019 Loans when due, failure to pay any fee or other amount due within two days after the same comes due, failure of any loan party to comply with any covenants or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is incorrect or misleading when made, events of bankruptcy and a change of control. The occurrence of an event of default would permit the lenders under the May 2019 Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

· Security

 

The Company has, subject to limited exceptions, granted general security over all assets of the Company and the Subsidiaries in connection with the May 2019 Loans.

( 21 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

Syndicated Loans

The Company entered into a credit agreement dated August 15, 2018 (the Syndicated Credit Agreement) with a syndicate of five financial institutions. Under the terms of the Syndicated Credit Agreement, the Company received a term loan (Syndicated Term Loan) of $100,000,000 (face value) and a revolving credit facility of $30,000,000, of which $11,900,000 was utilized as at May 30, 2019 (the Syndicated Revolving Facility, and together with the Syndicated Term Loan, the Syndicated Loans). The Syndicated Loans could be increased by an additional $40,000,000 subject to certain conditions. The Company used $11,900,000 of the Syndicated Revolving Facility to partly finance the Broward Acquisition and the Kissimmee Acquisition during the three months ended December 31, 2018. The proceeds of the Syndicated Term Loan were used to completely settle Akumin’s previous senior loan for $74,634,848, finance the Rose Acquisition in August 2018 and pay related debt issuance costs. Management determined the fair value of the Syndicated Term Loan to be its face value of $100,000,000, net of debt issuance costs of approximately $2.2 million. The fair value of the Syndicated Loans was determined based on management’s estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 14).

In accordance with the terms of the Syndicated Loans, the Company used part of the proceeds of the Term Loans to settle the Syndicated Loans on May 31, 2019 for $112,482,181 (face value of $111,900,000 and accrued interest and related fees of $582,181). The Company also recorded a fair value loss of $1,843,262 on the extinguishment of the Syndicated Loans, which was reflected in the consolidated statements of net income (loss) and comprehensive income (loss).

    September 30,     December 31,  
    2019     2018  
    $     $  
                 
Syndicated Loans           109,872,412  
Less: Current portion           2,500,000  
                 
            107,372,412  

 

Wesley Chapel Loan                

As part of the Rose Acquisition, the Company, through a subsidiary, assumed a senior secured loan (Wesley Chapel Loan) of $2,000,000 (face value) as of August 15, 2018 to finance the purchase of equipment and related development for a new clinic location around Tampa Bay, Florida. It has an annual interest rate of 5.0%, matures on August 15, 2023 and has monthly repayments of $37,742. The Wesley Chapel Loan was recognized at fair value of $1,908,456 on August 15, 2018 using an effective interest rate. The fair value was determined based on management’s estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 14).

( 22 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

             
    September 30,     December 31,  
    2019     2018  
    $     $  
Wesley Chapel Loan     1,536,266       1,796,186  
Less: Current portion     381,167       367,167  
                 
      1,155,099       1,429,019  

 

Subject to the provisions described below, the minimum annual principal payments with respect to the Wesley Chapel Loan (face value) are as follows:

 

    $  
October 1, 2019 to December 31, 2019     93,516  
2020     385,952  
2021     405,698  
2022     426,454  
2023     296,356  
         
      1,607,976  

The Wesley Chapel Loan provides for the following terms:

· Interest

5.0%.

· Payments

Monthly payments (principal and interest) of $37,742. The minimum principal payment schedule for the Wesley Chapel Loan is noted herein.

· Termination

August 15, 2023.

· Restrictive covenants

In addition to certain covenants, the Wesley Chapel Loan limits the Company’s ability to dispose of the assets of Akumin Corp., which is the guarantor to the Wesley Chapel Loan.

· Financial covenants

None.

( 23 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

· Events of default

Events of default under the Wesley Chapel Loan include, among others, failure to repay the Wesley Chapel Loan in full at maturity, or to pay any other sum due hereunder within ten days of the date when the payment is due, events of insolvency or disposition of all or substantially all of the assets related to the Rose Acquisition. The occurrence of an event of default would permit the lender to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

The Company has no events of default under the Wesley Chapel Loan as at September 30, 2019.

· Security

The Company has granted first security interest to the lender over the equipment and leasehold improvements acquired using the proceeds of the Wesley Chapel Loan.

10 Subordinated notes payable

 

    September 30,     December 31,  
    2019     2018  
    $     $  
Subordinated note           1,492,233  
Subordinated note – earn-out     180,657       169,642  
                 
      180,657       1,661,875  

 

As part of the Tampa Acquisition, Akumin FL entered into a subordinated 6% note and security agreement with the seller’s secured lender on May 11, 2018 (the Subordinated Note and Subordinated Note Lender, respectively) with a face value of $1,500,000 and a term of four years. The Subordinated Note was recognized at fair value of $1,490,932 on May 11, 2018 using an effective interest rate. The fair value was determined based on management’s estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 14).

In accordance with the terms of the Subordinated Note, the Company used part of the proceeds of the Term Loans to settle the principal outstanding under the Subordinated Note on May 31, 2019, together with accrued and unpaid interest, for $1,596,250 (face value of $1,500,000 and accrued interest of $96,250). The Company also recorded a fair value loss of $6,830 on the extinguishment of the Subordinated Note, which was reflected in the consolidated statements of net income (loss) and comprehensive income (loss).

According to the Subordinated Note, the Company is subject to an earn-out liability (Subordinated Note – Earn-out) of up to $4.0 million during the three-calendar year period beginning on January 1, 2019 and ending on December 31, 2021 (the Subordinated Note – Earn-out Period), subject to the satisfaction of certain revenue-based milestones, as follows:

( 24 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

a) The Subordinated Note – Earn-out for any given calendar year during the Subordinated Note – Earn-out Period shall be equal to 50% of any positive difference calculated by subtracting the Base Revenue ($16,000,000) for such calendar year from the Subordinated Note – Earn-out Revenue (defined below) for such calendar year.
b) The Subordinated Note – Earn-out Revenue for any calendar year during the Subordinated Note – Earn-out Period shall be the gross revenue generated by the centres related to the Tampa Acquisition during such calendar year.
c) If Subordinated Note – Earn-out Revenue for any calendar year of the Subordinated Note – Earn-out Period is less than or equal to $16,000,000, no Subordinated Note – Earn-out shall be payable for such calendar year.
d) The maximum aggregate amount of the Subordinated Note – Earn-out that may be earned over the Subordinated Note – Earn-out Period is $4,000,000.

The value of Subordinated Note – Earn-out has been estimated by management using a probability-weighted valuation technique; changes in the fair value of this liability are recognized in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss). Management estimated the fair value of Subordinated Note – Earn-out as at May 11, 2018 of $160,790 based on a discount rate of 8.75% and management’s estimated probability-weighted range of Subordinated Note – Earn-out Revenue during the Subordinated Note – Earn-out Period (it is considered a Level 3 liability as described in note 14). The Subordinated Note – Earn-out was revalued at $180,657 as at September 30, 2019 and the change in fair value was recognized in financial instruments revaluation in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss). As at September 30, 2019, the range of estimated undiscounted Subordinated Note – Earn-out payable is between $nil and $218,183.

Payments and termination

Under the Subordinated Note agreement, prior to May 11, 2022 (the Maturity Date), the Company may repay, without penalty, all or any portion of the Subordinated Note – Earn-out, and accrued but unpaid interest.

Restrictive covenants

The Subordinated Note agreement places certain limits on Akumin FL’s ability to declare dividends or other distributions, incur liens or indebtedness, make investments, undertake mergers or reorganizations or dispose of assets outside the ordinary course of business.

Financial covenants

None.

( 25 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

Events of default

Events of default under the Subordinated Note agreement include failure to pay any Subordinated Note – Earn-out, once earned, together with interest when due, defaults in complying with terms of the Subordinated Note agreement, and the occurrence of bankruptcy events relating to Akumin FL. The occurrence of an event of default would permit the Subordinated Note Lender to declare any Subordinated Note – Earn-out, once earned, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

Security

The Company has granted a security interest over all assets of Akumin FL as security for its obligations under the Subordinated Note. The Subordinated Note – Earn-out is subordinate to the intercompany loan from the Company to Akumin FL.

The Company is in compliance with the terms of the Subordinated Note agreement as at September 30, 2019.

( 26 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

11 Capital stock and warrants

 

The authorized share capital of the Company consists of an unlimited number of voting common shares, with no par value.

 

                                                 
    Common shares           Warrants           RSUs           Total  
    Number     Amount     Number     Amount     Number     Amount     Number     Amount  
          $           $           $           $  
                                                                 
December 31, 2017     51,416,323       83,771,904       1,196,407       1,310,661       1,611,316       469,967       54,224,046       85,552,532  
Issuance (i)     9,677,397       36,153,950       525,000       734,379       315,000       5,020,983       10,517,397       41,909,312  
RSUs and warrants exercised     1,277,555       3,820,569       (471,895 )     (302,130 )     (805,660 )     (2,819,803 )           698,636  
                                                                 
December 31, 2018     62,371,275       123,746,423       1,249,512       1,742,910       1,120,656       2,671,147       64,741,443       128,160,480  
Issuance (i)     6,250,000       23,437,500                         1,352,870       6,250,000       24,790,370  
RSUs and warrants exercised     593,997       2,593,329       (436,497 )     (569,733 )     (157,500 )     (712,450 )           1,311,146  
Warrants expired                 (256,002 )     (389,913 )                 (256,002 )     (389,913 )
                                                                 
September 30, 2019     69,215,272       149,777,252       557,013       783,264       963,156       3,311,567       70,735,441       153,872,083  

 

(i) RSU issuance amount includes stock-based compensation and costs related to RSUs during the period of the condensed interim consolidated financial statements.

( 27 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

During the nine months ended September 30, 2018, the following equity issuances occurred at the Company:

a) During the three months ended March 31, 2018, the following equity issuances occurred at the Company:

In accordance with the authorization from the Board in November 2017, 230,000 RSUs were granted to certain employees of the Company on January 1, 2018. Subsequently, on March 1, 2018, the Board authorized issuance of 35,000 RSUs on March 1, 2018 and 50,000 RSUs on March 12, 2018 to certain employees of the Company. Each granted RSU entitles the holder to one common share of the Company. These RSUs will vest as follows: 50% on the first anniversary of the date of grant and 50% on the second anniversary of the date of grant. RSUs are valued based on the market value of the common shares of the Company on the grant date (or the nearest working day prior to the grant date). Such value is classified as stock-based compensation over the vesting period for all RSUs awarded to employees or the Board.

b) During the three months ended June 30, 2018, the following equity issuances occurred at the Company:
i) The Company had 238,859 warrants that were due to expire on April 21, 2018 and 112,706 warrants that were due to expire on May 31, 2018. These warrants allowed warrant holders to purchase common shares of the Company on a 1:1 basis at an exercise price of $1.20 per common share of the Company. These warrants were exercised into common shares prior to expiry.
ii) On May 2, 2018, the Company completed a bought deal offering of its common shares by way of short form prospectus sale in each of the provinces of Canada, other than Quebec. A total of 8,750,000 common shares of the Company were sold at a price of $4.00 per common share, for gross proceeds of $35,000,000 (the Offering). The related issuance costs were approximately $1.8 million, which were deducted from common equity. The Offering was underwritten by a syndicate of underwriters (the Underwriters). The Underwriters were granted 525,000 broker warrants (Broker Warrants) in connection with the Offering, each such Broker Warrant entitling the holder to acquire one common share of the Company at a price of $4.00 per common share for a 24-month period following the closing of the Offering. The fair value of these warrants, recognized as a deduction of issued capital, was determined to be $1.3988 per warrant using the Black-Scholes option pricing model based on the following assumptions: historical common share price volatility of approximately 62%; remaining life of two years; price per common share on grant of warrants of $4.00; expected dividend yield of zero; and annual risk free interest rate of 1.93%.
iii) On May 24, 2018, the Company announced that PMI completed its previously announced acquisitions of all of the outstanding non-controlling interests in seven of its existing Texas based diagnostic imaging centres (the Acquisitions). The Acquisitions related to certain operations carried on in Austin, Fort Worth, Frisco, Grapevine/Colleyville, Irving, Plano and Round Rock. The aggregate consideration paid for the Acquisitions was approximately $21.6 million, comprised of an aggregate cash payment of approximately $17.9 million and the issuance of approximately $3.7 million in common shares of the Company (927,397 shares at $4.00 per share). The cash consideration included approximately $0.2 million paid to a non-wholly owned subsidiary, Preferred Imaging of Tarrant County, LLC, that was consolidated in the Company’s results.
( 28 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

c) During the three months ended September 30, 2018, the following equity issuances occurred at the Company:
i) During March 2017 the Company had issued 300,825 warrants to purchase common shares on a 1:1 basis at an exercise price of $2.30 per common share. These warrants were scheduled to expire on March 10 and 17, 2019. During the three months ended September 30, 2018, 120,330 of these warrants were exercised into common shares.

During the nine months ended September 30, 2019, the following equity issuances occurred at the Company:

a) During the three months ended March 31, 2019, the following equity issuances occurred at the Company:
i) During March 2017, the Company issued 300,825 warrants to purchase common shares on a 1:1 basis at an exercise price of $2.30 per common share. These warrants were scheduled to expire on March 10 and 17, 2019. During the three months ended September 30, 2018, 120,330 of these warrants were exercised into common shares. The remaining 180,495 warrants were exercised into common shares prior to expiry.
ii) The Board had granted 315,000 RSUs to certain employees of the Company between January 1 and March 12, 2018. Fifty percent of these RSUs vested between January 1 and March 12, 2019 in accordance with the terms of the RSU Plan and 25,000 of these vested RSUs were settled for common shares prior to March 31, 2019.
b) During the three months ended June 30, 2019, the following equity issuances occurred at the Company:
i) The Company issued approximately $23 million in equity (6,250,000 common shares at $3.75 per share, the closing price as of May 31, 2019) to certain sellers in connection with the ADG Acquisitions.
ii) During August 2017, the Company issued 512,004 warrants to purchase common shares on a 1:1 basis at an exercise price of $3.50 per common share. The expiry date for these warrants was August 8, 2019. During the three months ended June 30, 2019, 256,002 of these warrants were exercised into common shares.
iii) The Board had granted 315,000 RSUs to certain employees of the Company between January 1 and March 12, 2018. Fifty percent of these RSUs vested between January 1 and March 12, 2019 in accordance with the terms of the RSU Plan and 25,000 of these vested RSUs were settled for common shares prior to March 31, 2019. The remaining 132,500 of these vested RSUs were settled for common shares prior to June 30, 2019.
( 29 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

c) During the three months ended September 30, 2019, the following equity issuances occurred at the Company:
i) During August 2017, the Company issued 512,004 warrants to purchase common shares on a 1:1 basis at an exercise price of $3.50 per common share. The expiry date for these warrants was August 8, 2019. During the three months ended June 30, 2019, 256,002 of these warrants were exercised into common shares. The remaining 256,002 of these warrants were not exercised into common shares and expired on August 8, 2019.

The stock-based compensation related to RSUs, recognized in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss) for the three and nine months ended September 30, 2019, was $441,532 and $1,352,870, respectively (2018 – $1,324,595 and $4,166,356).

The stock-based compensation related to options, recognized in the condensed interim consolidated statements of net income (loss) and comprehensive income (loss) for the three and nine months ended September 30, 2019, was $411,056 and $1,452,671, respectively (2018 – $99,403 and $298,209).

12 Commitments and contingencies

The Company is involved in certain legal matters arising from time to time in the normal course of business. The Company records provisions that reflect management’s best estimate of any potential liability relating to these matters. The resolution of these matters is not expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows.

13 Segmented financial information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer. The Company has one reportable segment, which is outpatient diagnostic imaging services.

14 Risk management arising from financial instruments

The carrying value of cash, accounts receivable, accounts payable and accrued liabilities and leases approximates their fair value given their short-term nature.

The carrying value of the non-current portion of leases approximates their fair value given the difference between the discount rates used to recognize the liabilities in the condensed interim consolidated balance sheets and the market rates of interest is insignificant. The estimated fair values of other non-current assets and liabilities were as follows:

( 30 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

             
    September 30,     December 31,  
    2019     2018  
    $     $  
Loans to related parties     331,100       495,000  
                 
Syndicated loans payable           110,244,000  
May 2019 loans payable     338,106,500        
Wesley Chapel Loan payable     1,565,700       1,823,000  
Subordinated notes payable           1,476,000  
Subordinated notes – earn-out     180,657       169,642  
ADG Acquisition – earn-out     20,534,510        
Derivative financial instruments     1,223,989       (16,014 )
                 
      361,611,356       113,696,628  

 

Financial instruments recorded at fair value on the condensed interim consolidated balance sheets are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

· Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;
· Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability; either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
· Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The loans to related parties, the May 2019 Loans, Syndicated Loans, Wesley Chapel Loan, Subordinated Notes, Subordinated Notes – Earn-out and ADG Acquisition – Earn-out were measured at fair value under the Level 3 category on recognition. The Subordinated Notes – Earn-out and ADG Acquisition – Earn-out are subsequently remeasured at fair value under the Level 3 category.

There were no transfers between levels during the nine months ended September 30, 2019 and the twelve months ended December 31, 2018.

Financial instruments are classified into one of the following categories: amortized cost, fair value through profit or loss and fair value through other comprehensive income.

The following table summarizes information regarding the carrying value of the Company’s financial instruments:

( 31 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

    September 30,     December 31,  
    2019     2018  
    $     $  
             
Cash     17,475,988       19,326,412  
Accounts receivable     77,163,237       29,810,501  
Loans to related parties     333,333       500,000  
                 
Financial assets measured at amortized cost     94,972,558       49,636,913  
                 
Accounts payable and accrued liabilities     24,333,175       16,865,477  
Short-term portion of senior loans payable     3,701,167       2,867,167  
Short-term portion of leases     10,108,461       851,183  
Long-term portion of senior loans payable     316,848,786       108,801,431  
Long-term portion of leases     122,176,433       3,325,832  
Subordinated notes payable           1,492,233  
                 
Financial liabilities measured at amortized cost     477,168,022       134,203,323  
                 
Subordinated notes – earn-out     180,657       169,642  
ADG Acquisition – earn-out     20,534,510        
Derivative financial instruments     1,223,989       (16,014 )
                 
Measured at fair value through profit or loss     21,939,156       153,628  
15 Basic and diluted income per share
                         
    Three-month
period ended
September 30,
2019
$
    Three-month
period ended
September 30,
2018
$
    Nine-month
period ended
September 30,
2019
$
    Nine-month
period ended
September 30,
2018
$
 
Net income attributable to common shareholders     1,988,164       194,996       3,195,837       2,790,690  
Weighted average common shares outstanding                                
Basic     69,215,272       61,449,209       65,517,233       56,925,714  
Diluted     70,736,802       62,827,298       67,038,763       58,303,803  
                                 
Income per share                                
Basic     0.03       0.00       0.05       0.05  
Diluted     0.03       0.00       0.05       0.05  

( 32 )
 

Akumin Inc.

Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

September 30, 2019

 

 

(expressed in US dollars unless otherwise stated)

 

16 Settlement costs (recoveries)

During the nine months ended September 30, 2019, the Company experienced net settlement recoveries of $1,438,662 (2018 – settlement costs of $29,494). During the three months ended September 30, 2019, the Company settled certain claims affecting PMI relating to periods arising prior to August 9, 2017, the date the Company acquired PMI. During the nine months ended September 30, 2019, the Company received an aggregate of approximately $4.1 million from the escrow fund maintained for the sellers of PMI as a result of indemnity claims under the purchase agreement for PMI to fully and finally settle the claims affecting PMI.

17 Subsequent events
i) The Board had granted 315,000 RSUs to certain employees of the Company between January 1 and March 12, 2018. Fifty percent of these RSUs vested between January 1 and March 12, 2019 in accordance with the terms of the RSU Plan and the remaining unvested RSUs will vest between January 1 and March 12, 2020. Twenty-five thousand RSUs from these unvested RSUs were settled for common shares on October 1, 2019 in accordance with the terms of the RSU Plan.
ii) On October 4, 2019, the Company acquired, through a subsidiary, three outpatient diagnostic imaging centres near West Palm Beach, Florida, for cash consideration of approximately $18 million. This acquisition was mostly financed through the delayed draw portion of the Company’s Term Loans of $16 million and approximately $1 million under the Company’s revolving credit facility, both under the May 2019 Credit Agreement.
( 33 )